▲ Peaking
Health
🔮 fades
The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify
A $50 Medicare GLP‑1 price lock promises savings, but millions of eligible patients remain shut out.
Glp-1
64 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Glp-1
This hub groups 64 separate news trends connected to Glp-1, spanning June 18, 2026 through August 26, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 504 article observations and 480 source signals, led by Health, Business, Entertainment coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Health
🔮 fades ✓
Unexpected GLP-1 side effect? Studies show the meds may help people with addictions
New studies suggest GLP-1 medications, used for weight loss, may also help treat addiction.
◼ Archived
Health
🔮 fades ✓
Smart probiotics can sense high blood sugar and release GLP-1 on demand
A new probiotic can sense high blood sugar and release a diabetes drug on demand, potentially revolutionizing treatment.
◼ Archived
Health
🔮 fades ✓
Promising new weight loss and diabetes treatment helps burn fat while keeping muscle in preclinical study
A new treatment could revolutionize weight loss and diabetes management by targeting fat while preserving muscle.
◼ Archived
Entertainment
🔮 fades ✓
Justin Hartley reacts to ‘This Is Us’ costar Chrissy Metz’s use of GLP-1s, weight loss
Justin Hartley's public support for Chrissy Metz's GLP-1 weight loss journey has reignited conversations about celebrity health choices.
◼ Archived
Health
🔮 fades ✓
This Underconsumed Nutrient Supports Digestion & So Much More
A specific nutrient is gaining attention for its role in digestion and beyond, sparking interest in precision nutrition.
◼ Archived
Health
🔮 fades ✓
Could GLP-1s help with alcohol use disorder? A Philly VA doctor is leading a national trial to find out.
A national trial is exploring whether GLP-1s, known for weight loss, can also help with alcohol use disorder.
◼ Archived
Health
🔮 fades ✓
GLP-1s Left Their Hair 'Falling Out In Fistfuls'
Recent reports indicate that users of GLP-1 receptor agonists are experiencing significant hair loss, sparking medical interest in these medications.
◼ Archived
Health
🔮 fades ✓
A pill that mimics exercise? Early results on drug designed to maintain both weight loss and muscle mass
A drug designed to mimic exercise has passed its first human test, sparking interest in the medical community.
◼ Archived
Entertainment
🔮 fades ✓
‘Weight To Date’ Series Set At Netflix; Marks IPC’s First Sale Since Founders Left Sony Pictures TV
Netflix is casting singles who have undergone dramatic weight loss for a new dating series.
◼ Archived
Health
🔮 fades ✓
GLP-1s May Be Working in an Entirely Different Way Than We Thought
New research suggests that popular weight-loss drugs may work differently than previously understood.
◼ Archived
Health
🔮 fades ✓
Type 2 Diabetes: GLP-1 Mounjaro May Lower Heart Attack Risk
A popular diabetes drug may also protect against heart attacks, but the mechanism is still unclear.
◼ Archived
Entertainment
🔮 fades ✓
Why Chrissy Metz Finally Said Yes to a GLP-1 After Being a "Skeptic" for Years
Chrissy Metz's public embrace of GLP-1 drugs after years of skepticism has sparked a wave of celebrity conversations about weight loss.
◼ Archived
Health
🔮 fades ✓
7 Surprising Benefits Of GLP-1s That Are Not About Weight Loss
Medical discourse on GLP-1 medications is shifting beyond weight loss as new research highlights brain mechanisms and non-weight-related health outcomes.
◼ Archived
Health
🔮 fades ✓
Lilly's weight-loss pill gets UK regulator's nod
The UK has approved a new weight-loss pill, marking a significant shift in obesity treatment options.
◼ Archived
Entertainment
🔮 fades ✓
Kendra Wilkinson hits the gym for first time in 2 years amid GLP-1 weight loss journey: ‘I don’t know where to start’
Kendra Wilkinson has returned to the gym after a two-year hiatus, marking a shift in her fitness routine amidst a GLP-1 weight loss journey.
◼ Archived
Business
🔮 fades ✓
Amazon to Offer GLP-1 Weight-Loss Drugs to Medicare Part D Patients
Amazon Pharmacy is now delivering GLP-1 weight-loss drugs to Medicare patients for $50 a month.
◼ Archived
Business
🔮 fades ✓
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Novo Nordisk faces intensifying competition from Eli Lilly in the global GLP-1 weight-loss market as its early industry lead faces significant pressure.
◼ Archived
Business
CVS Health Launches Eli Lilly GLP-1 Partnership, Lifts Outlook as Profit Increases
CVS Health is expanding access to weight-loss treatments through a new Eli Lilly partnership, resulting in an updated financial outlook for the company.
◼ Archived
Business
🔮 fades ✓
Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand
Eli Lilly's stock surges as demand for its weight-loss drugs continues to drive revenue growth.
◼ Archived
Business
🔮 fades ✓
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Divergent earnings reports this week reveal a surge in pharmaceutical demand alongside cooling momentum in the digital advertising sector.
◼ Archived
Business
🔮 fades ✓
Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
Eli Lilly is expanding access to its experimental obesity drug, Retatrutide, ahead of approval.
◼ Archived
Health
🔮 holds ✗
GLP-1 use tied to obesity decline, but doctors warn of alarming misuse
GLP-1 drugs are linked to a decline in obesity, but doctors are raising alarms about misuse.
◼ Archived
Health
🔮 fades ✓
Ozempic is changing workplace etiquette
The rise of GLP-1 medications is rewriting the social norms of the modern office and challenging long-standing boundaries regarding body image.
◼ Archived
Business
🔮 fades ✓
Compounded GLP-1 drugs creating concern among doctors and FDA
Six outlets report that the FDA is scrutinizing compounded GLP-1 drugs, raising concerns among doctors about potential health risks.
◼ Archived
Health
🔮 fades ✗
Scientists Searching 6,000 Drugs For Anti-Aging Properties Found One Hiding in Plain Sight
Researchers investigating 6,000 existing medications have identified potential links between common drugs and slowed biological aging.
◼ Archived
Health
🔮 fades ✓
Should We Be Concerned About Muscle Loss With GLP-1s?
Medical experts are raising alarms over the risk of muscle loss and increased frailty in older adults using GLP-1 weight loss medications.
◼ Archived
Health
🔮 fades ✓
Rare eye disorder linked to Ozempic-like medications
Health regulators and legal firms are responding to a linked risk of rare blindness and eye disorders associated with GLP-1 weight-loss medications.
◼ Archived
Health
🔮 fades ✓
Pharmacists Warn About Diet on Weight Loss Drugs
Pharmacists and health outlets are highlighting the critical role of specific nutrition strategies for patients prescribed GLP-1 weight loss medications.
◼ Archived
Health
🔮 fades ✓
High-protein soft pretzels and soups are on the menu as Philly’s iconic food brands compete for GLP-1 consumers
Food manufacturers are integrating high-protein formulations into popular snacks and beverages to capture consumer interest in diet-focused products.
◼ Archived
Health
🔮 fades ✓
Weight loss drugs linked to increased risk of hair loss, researchers say
14 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 holds ✗
GLP-1 use rising rapidly among US adolescents and young adults, study finds
GLP-1 weight-loss medications are seeing a rapid surge in use among U.S. adolescents and young adults.
◼ Archived
Health
🔮 fades ✗
GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds
New economic research identifies a correlation between GLP-1 weight-loss drug usage and a 17% reduction in employee sick leave.
◼ Archived
Business
🔮 fades ✗
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the rival company used false and misleading advertising regarding weight-loss drug efficacy.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the use of misleading and deceptive advertising for GLP-1 weight-loss drugs.
◼ Archived
Health
🔮 holds ✓
Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and blindness - WSB-TV
Reports and litigation are emerging over a potential link between GLP-1 weight loss medications and a rare, blinding eye condition.
◼ Archived
Health
🔮 fades ✓
This GLP-1 retreat changed how I think about weight loss
GLP-1 medications are sparking broader conversations about weight loss retreats, medical benefits beyond weight, and the psychological impact of stigma.
◼ Archived
Health
🔮 fades ✗
24 GLP-1 Users Reveal The Good, The Bad, And The Shocking Side Effects
Rapid growth in GLP-1 drug adoption is sparking new discussions on side effects, lifestyle requirements, and the social dilemmas of disclosure.
◼ Archived
Health
🔮 fades ✓
GLP-1’s Reduce Binge Eating Symptoms
Research suggests GLP-1 medications like Ozempic and Wegovy may provide a promising treatment for binge eating disorder.
◼ Archived
Health
🔮 fades ✓
She Used Weight-Loss Drugs From a Telehealth Company, Then a GLP-1 Overdose Sent Her to the ER
Rising concerns over GLP-1 weight-loss drug overdoses are linked to dosing errors and the use of telehealth services.
◼ Archived
Health
🔮 fades ✓
Weight-loss drugs didn't improve mental health or job prospects
Recent analyses suggest weight-loss drugs may not deliver broader improvements to mental health, job prospects, or overall quality of life.
◼ Archived
Health
🔮 holds ✗
Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread
Medical discussions are intensifying over whether GLP-1 medications like Ozempic can prevent cancer or influence oncology recovery.
◼ Archived
Health
🔮 fades ✗
Low-protein ‘longevity diet’ helped mice live healthier, leaner lives: Study
A new study suggests a low-protein 'longevity diet' may help reduce body fat and increase natural GLP-1 levels.
◼ Archived
Business
🔮 fades ✓
Why your health plan doesn’t cover GLP-1s, according to a top insurance exec
Insured patients are facing challenges accessing GLP-1 weight-loss drugs as coverage policies and payment models shift.
◼ Archived
Health
🔮 fades ✓
New weight loss pill that’s beating oral Ozempic
A new oral GLP-1 weight-loss pill is showing results that outperform oral Ozempic in major clinical trials.
◼ Archived
Health
🔮 fades ✓
What are ‘Ozempic feet’? Doctors warn of surprising weight-loss side effect
Doctors are warning GLP-1 medication users about 'Ozempic feet,' a surprising side effect emerging as weight-loss drugs grow in popularity.
◼ Archived
Business
🔮 fades ✓
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Novo Nordisk has entered into a partnership with Vivani to develop a long-acting semaglutide implant designed for weight management.
◼ Archived
Health
🔮 fades ✓
Ozempic Face, Blindness Claims, And Billions In Potential Damages: The GLP-1 Reckoning
Public scrutiny regarding the mental, physical, and legal implications of GLP-1 receptor agonists intensifies amid reports of potential litigation.
◼ Archived
Health
🔮 fades ✗
Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs
Employers and public health programs are limiting access to GLP-1 obesity drugs due to rising costs and budget constraints.
◼ Archived
Business
🔮 fades ✓
Nestlé to Tweak Some Food Recipes to Appeal to Duller GLP-1 Palates
Nestlé is adjusting food recipes as the rise of GLP-1 weight-loss drugs alters consumer taste preferences and shopping habits.
◼ Archived
Business
🔮 fades ✗
11% of Americans Are Currently Taking a GLP-1 Weight Loss Drug Like Wegovy
GLP-1 weight loss drugs are being used by a record number of Americans.
◼ Archived
Health
🔮 fades ✓
Wegovy weight loss pill now available in UK
Wegovy has launched a daily oral pill for weight management in the UK, marking a shift from injectable treatments to pharmacy-available medication.
◼ Archived
Business
🔮 fades ✗
Eli Lilly's Market Cap Balloons, Again, On This IPO's Setback
Eli Lilly's market value surges as Kailera's weight-loss pill faces market setbacks despite successful clinical efficacy in China.
◼ Archived
Health
🔮 fades ✗
Ozempic skin side effects are more common than you think
The rise of GLP-1 medications like Ozempic is creating a new surge in demand for plastic surgery and aesthetic medicine to treat skin side effects.
◼ Archived
Health
🔮 fades ✓
How easy is it to get weight-loss drugs online? Secret shoppers from Yale found out.
A Yale secret shopper study reveals significant gaps in the online prescribing process for GLP-1 obesity medications.
◼ Archived
Health
🔮 fades ✓
People Are Sharing The Things They Think Will Be “Inevitable Outcomes” Of GLP-1s Over The Next 20 Years
Public discourse and clinical research are shifting toward the long-term psychological and addictive-behavior impacts of GLP-1 medications.
◼ Archived
Health
🔮 fades ✓
Peptide hype is at an all-time high
Peptides have emerged as a dominant wellness trend, sparking a commercial gold rush alongside growing warnings about unregulated black-market usage.
◼ Archived
Business
🔮 fades ✓
Seniors in Medicare are about to get landmark obesity drug coverage
Starting July 1, 2026, Medicare will cover GLP-1 weight-loss drugs for seniors, marking a significant expansion in obesity treatment access.
◼ Archived
Business
🔮 fades ✓
Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage
Employers are reconsidering coverage for popular GLP-1 weight loss drugs, leaving patients and insurers in limbo.
◼ Archived
Health
🔮 holds ✗
GLP-1 weight loss drugs may be misused by patients with eating disorders: Study
New research indicates that GLP-1 receptor agonists, including Ozempic, are being misused by individuals with eating disorders.